Reversal of Pipecuronium-induced Neuromuscular Blockade With Sugammadex During Sevoflurane Anesthesia
Launched by TAMAS VEGH, MD · Jun 27, 2025
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how well and how safely the drug Sugammadex can reverse the effects of a muscle relaxant called Pipecuronium during surgery when anesthesia is given with a medicine called Sevoflurane. Muscle relaxants are used during surgery to help keep the body still, but sometimes their effects can last longer than needed, which might cause problems after the operation. This study aims to understand how quickly and safely Sugammadex can help patients recover normal muscle movement after surgery, as well as to check for any allergic reactions during or after the procedure.
The study will include about 80 adult patients, aged 18 to 65, who are having planned general or brain surgeries that last at least 40 minutes and require a breathing tube. Participants should be generally healthy with a normal body weight and have no serious muscle, liver, or kidney problems. During the surgery, patients will be carefully monitored using standard equipment to track their heart, breathing, and muscle function. After surgery, doctors will measure how long it takes for muscle strength to return to normal after giving Sugammadex. The study also focuses on making sure there are no leftover effects from the muscle relaxants and watching for any allergic reactions. If you qualify and agree to join, you can expect routine care with extra monitoring to ensure your safety throughout the procedure.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 80 adult general surgery and neurosurgical patients are enrolled in the study after giving an informed written consent regarding their participation.
- • Age: between 18-65 years;
- • ASA score: 1-3;
- • BMI 18.5-25 (normal body weight);
- • Males and females were recruited in an equal ratio;
- • Minimal surgical time of at least ≥ 40 minutes;
- • Procedures requiring endotracheal intubation;
- Exclusion Criteria:
- • Diseases affecting neuromuscular function (myopathies, severe liver and kidney failure);
- • Drugs affecting neuromuscular function (magnesium, aminoglycosides);
- • Difficult airway, or anticipated difficult intubation;
- • Pregnancy (a pregnancy test is performed in women of childbearing age to rule out pregnancy);
- • Breast-feeding;
- • Acute surgery;
- • COPD
- • Glaucoma
- • History of previous allergic/anaphylactic reactions
About Tamas Vegh, Md
Dr. Tamas Vegh, MD, is an esteemed clinical trial sponsor known for his commitment to advancing medical research and improving patient outcomes. With a robust background in clinical medicine and a focus on innovative therapeutic approaches, Dr. Vegh leads trials that explore novel treatments and interventions across various medical disciplines. His dedication to rigorous scientific methodology and ethical standards ensures that each study not only contributes to the body of medical knowledge but also prioritizes participant safety and well-being. Through collaboration with leading research institutions and healthcare professionals, Dr. Vegh aims to bridge the gap between research and clinical practice, ultimately enhancing the standard of care for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Debrecen, , Hungary
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported